Protalix Stock Is Trading Higher On Meeting Request To FDA For Fabry Disease Candidate Application

by Vandana Singh, Benzinga Editor

August 2, 2021 8:03 AM | 1 min read |

Protalix BioTherapeutics Inc PLX has submitted a Type A Meeting request to the FDA regarding PRX-102 Complete Response Letter it received in April.
The FDA issued the response letter for pegunigalsidase alfa (PRX-102) in Fabry disease, though no reasons were cited in the letter.
The Type A Meeting is expected to occur within 30 days of the FDA's receipt of the meeting request.
Price Action: PLX shares are up 4.63% at $1.58 during the premarket session on the last check Monday.
Related content: Benzinga's Full FDA Calendar.

Posted In: Biotech News Penny Stocks Health Care FDA General Briefs Fabry disease

Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.